Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Apiam Animal Health (ASX:AHX), a veterinary services group, has been undergoing leadership change. In August 2025, Tamim reported Apiam's FY25 results, with revenue up 1.4%, alongside strategic updates. In June 2025, Tamim noted Dr Chris Richards would step down as CEO and managing director after more than nine years. Apiam Animal Health operates in the Healthcare sector within the Healthcare Providers and Services industry, and Thesis Tracker has captured 2 comments from 1 fund manager, Tamim Funds Management. Headquartered in Bendigo, Victoria, Apiam provides veterinary products and services for production animals such as dairy cattle, pigs and beef, as well as companion animals and horses, through a network of rural and regional clinics across Australia, combining clinical services with product distribution and benefiting from long-term demand in agriculture and pet care, and was the subject of corporate interest.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Tamim Funds Management have invested in Apiam Animal Health Ltd (ASX:AHX).
Tamim highlights strategic updates and steady revenue from Apiam's rural veterinary network serving production and companion animals.
Tamim notes modest revenue growth of 1.4% and the departure of long-serving CEO Chris Richards, introducing leadership transition risk.
Apiam Animal Health Limited (AHX) provides veterinary products and services for production animals, companion animals, and equine animals. The company operates in the animal health sector, serving veterinary care needs across livestock, pet, and horse segments. This description highlights Apiam Animal Health Limited’s business focus for investors reviewing company and fund manager commentary.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.